Stocks Health care AQST
NASDAQ · Health careAquestive Therapeutics, Inc. (AQST)
Aquestive Therapeutics, Inc. brought in $54.1M of revenue over the twelve months to June 30, 2026, up 22.6% from a year earlier. It posted a net loss of $78.2M. In fiscal 2025 capital spending exceeded operating cash flow by $53M. At June 30, 2026 it held $98.5M in cash against $55M of debt. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 11, 2026.
What Aquestive Therapeutics, Inc. does
Aquestive Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AQST.
Revenue and profit by year
Key figures
| Fiscal year | Revenue | Net income | Diluted EPS | Free cash flow |
|---|---|---|---|---|
| 2025 | $44.5M | -$83.8M | -$0.78 | -$53M |
| 2024 | $57.6M | -$44.1M | -$0.51 | -$35.9M |
| 2023 | $50.6M | -$7.9M | -$0.13 | -$7.4M |
| 2022 | $47.7M | -$54.4M | -$1.12 | -$10.8M |
| 2021 | $50.8M | -$70.5M | -$1.85 | -$33.9M |
| 2020 | $45.8M | -$55.8M | -$1.66 | -$46M |
Latest SEC filings
What Aquestive Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.
- September 25, 2026
- September 17, 2026
- August 11, 2026Quarterly report 10-Q · period to June 30, 2026
- August 11, 2026
- August 10, 2026
- July 27, 2026Passive stake changed SCHEDULE 13G/A
- July 9, 2026
- June 26, 2026
- June 10, 2026
- May 13, 2026Quarterly report 10-Q · period to March 31, 2026
Questions about AQST
What does Aquestive Therapeutics, Inc. do?
Aquestive Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker AQST.
Is Aquestive Therapeutics, Inc. profitable?
No. Over the twelve months to June 30, 2026 it reported a net loss of $78.2M on revenue of $54.1M.
How much revenue does Aquestive Therapeutics, Inc. make?
Over the twelve months to June 30, 2026 Aquestive Therapeutics, Inc. reported revenue of $54.1M. That is 22.6% more than a year earlier.
When did Aquestive Therapeutics, Inc. last report?
Its most recent periodic report is the quarterly report (10-Q) filed on August 11, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the investor disclosure from September 25, 2026.
Similar companies
Follow AQST
Get an email when Aquestive Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.
Follow AQST: get an email when it filesWhere the numbers come from
Financial figures are the values Aquestive Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.
Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.